Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4557779 | 0.85 | HDAC3 (0.40) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL4307307 | 0.80 | CA2 (0.35) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL6606570 | 0.70 | CTSG (0.43) | — | |
| SCHEMBL2502740 | 0.69 | CCNB2 (0.39) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL26302403 | 0.67 | CTSS (0.46) | CYP2D6CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL17731584 | 0.67 | CASP1 (0.54) | — | |
| SCHEMBL28643149 | 0.65 | CYP2D6 (0.42) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL30826518 | 0.65 | CYP2D6 (0.42) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL28643147 | 0.65 | CYP2D6 (0.42) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL25192292 | 0.64 | MAPT (0.48) | CYP2D6HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261831-A1 | Ligands and libraries of ligands | WELLS JIM | 2008-10-23 | — | — | US | disclosed |
| EP-1939625-A2 | Methods for ligand discovery | Sunesis Pharmaceuticals, Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1441228-B1 | An extended tethering approach for rapid identification of ligands | SUNESIS PHARMACEUTICALS INC (US) | 2006-06-28 | — | — | EP | disclosed |
| US-6998233-B2 | Methods for ligand discovery | SUNESIS PHARMACEUTICALS, INC. (US) | 2006-02-14 | — | — | US | disclosed |
| US-20050186630-A1 | Extended tethering approach for rapid identification of ligands | ERLANSON DANIEL A (US) | 2005-08-25 | — | — | US | disclosed |
| US-6919178-B2 | Extended tethering approach for rapid identification of ligands | SUNESIS PHARMACEUTICALS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20050142614-A1 | Methods for ligand discovery | WELLS JIM (US) | 2005-06-30 | — | — | US | disclosed |
| EP-1441228-A1 | An extended tethering approach for rapid identification of ligands | Sunesis Pharmaceuticals, Inc. (US) | 2004-07-28 | — | — | EP | disclosed |
| US-20040043426-A1 | Methods for ligand discovery | WELLS JIM (US) | 2004-03-04 | — | — | US | disclosed |
| EP-1337853-A2 | AN EXTENDED TETHERING APPROACH FOR RAPID IDENTIFICATION OF LIGANDS | Sunesis Pharmaceuticals, Inc. (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20020155505-A1 | Methods for ligand discovery | SUNESIS PHARMACEUTICALS, INC. | 2002-10-24 | — | — | US | disclosed |
| US-20020150947-A1 | Extended tethering approach for rapid identification of ligands | SUNESIS PHARMACEUTICALS, INC. | 2002-10-17 | — | — | US | disclosed |
| WO-2002042773-A2 | AN EXTENDED TETHERING APPROACH FOR RAPID IDENTIFICATION OF LIGANDS | SUNESIS PHARMACEUTICALS, INC. (US) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043426-A1 | Methods for ligand discovery | ADGRF1, VCAM1, LDLR | CYP2D6 4295/4885HDAC3 1338/4885HDAC1 1832/4885 |
| US-20020155505-A1 | Methods for ligand discovery | ADGRF1, VCAM1, LDLR | CYP2D6 4295/4885HDAC3 1338/4885HDAC1 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.